Randomized phase II study of TS-1/ CPT-11 [irinotecan] versus TS-1/TXL [paclitaxel] in advanced/recurrent gastric cancer.

Trial Profile

Randomized phase II study of TS-1/ CPT-11 [irinotecan] versus TS-1/TXL [paclitaxel] in advanced/recurrent gastric cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Paclitaxel (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2010 Results presented at the 35th Congress of the European Society for Medical Oncology (ESMO).
    • 04 Jun 2010 Final results have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 03 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top